- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03412292
MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)
A Phase I Trial of MAX-40279 Given Orally to Subjects With Acute Myelogenous Leukemia (AML)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The class III receptor tyrosine kinase FMS-related tyrosine kinase 3 (FLT3), is mutated and activated in about 30% of adult patients with AML. The mutations involve either an internal tandem duplication (ITD) (in about 25% of AML patients) or a point mutation in the tyrosine kinase domain (TKD) (in about 7% of patients). Patients with mutations in FLT3, particularly those with ITD mutations, have a worse prognosis, with lower rate of complete remission, and lower overall survival . Thus, inhibition of activated FLT3 kinase by a pharmacologic agent is an attractive therapeutic strategy in AML.
The aberrant of fibroblast growth factor receptor (FGFR) might be a major reason fot resistance to targeted therapies, and FGFR inhibitors significantly suppress leukemia development in vivo.
MAX-40279 is a dual inhibitor of FLT3 and FGFR. Our goal is to develpe this uqiue dual inhibitor to be a more effective and wider use for AML treatment than the current known FLT3 inhibitors.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Chun Fong, MD
- Phone Number: +61394965000
- Email: chun.fong@austin.org.au
Study Locations
-
-
New South Wales
-
Darlinghurst, New South Wales, Australia, 2010
- Recruiting
- St Vincent's Hospital Sydney Limited
-
Contact:
- Kent Robert
-
Dubbo, New South Wales, Australia, 2830
- Recruiting
- Western NSW Local Health District
-
Contact:
- Millard Stephen
-
Principal Investigator:
- Douglas Lenton, DM
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Recruiting
- Monash Health
-
Contact:
- Uhe Micheleine
- Phone Number: +6139594 4044
-
Heidelberg, Victoria, Australia, 3084
- Recruiting
- Austin Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and/or females over age 18
- Ability to understand the purposes and risks of the trial and signed informed consent forms approved by the investigator's Institutional Review Board (IRB)/Independent Ethics Committee (IEC) of the trial site was obtained before the entering the trial
- Subject has morphologically documented primary AML or AML secondary to myelodysplastic syndrome (MDS) as defined by the World Health Organization (WHO) criteria for which no established standard therapy is available
- ECOG performance status of 0 to 2
- Persistent chronic clinically significant nonhematological toxicities from prior treatment (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, radiation, HSCT, or surgery) must be Grade ≤ 1
- In the absence of rapidly progressing disease clearly documented by the investigator, the interval from prior treatment to time of MAX-40279 administration will be at least 2 weeks (14 days) for prior cytotoxic agents or at least 5 half-lives for prior noncytotoxic agents, including immunosuppressive therapy post HSCT
Acceptable liver function defined below:
- Total bilirubin ≤ 1.5 times upper limit of normal range (ULN)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 times ULN;
Acceptable renal function defined below:
• Serum creatinine ≤ 1.5 times ULN or calculated creatinine clearance (by the Cockcroft-Gault formula) ≥ 60 mL/min
Acceptable coagulation status defined below:
- Prothrombin time < 1.3 times ULN
- Partial thrombin time < 1.3 times ULN
- No clinically significant abnormalities in urinalysis
- Female participants of child bearing potential agree not to be pregnant or lactating during the study and for three months following the last dose of study drug. Both men and women of reproductive potential must agree to use a highly effective method of birth control during the study and for three months following the last dose of study drug. A highly effective method of contraception is defined as one that results in a low failure rate, i.e., less than 1% per year, when used consistently and correctly
Exclusion Criteria:
- Disease diagnosis of acute promyelocytic leukemia
- Previously treated malignancies other than the current disease, except for adequately treated non-melanoma skin cancer, in situ cancer, or other cancer from which the subject has been disease-free for at least 5 years at the trial entry
- Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
- Major surgery, other than diagnostic surgery, within 4 weeks prior to the trial entry, without complete recovery
- Percutaneous coronary intervention conducted within 6 months prior to the trial entry for cardiac infarction or angina pectoris
- Seizure disorders requiring anticonvulsant therapy
- Taking a medication that prolongs QT interval and has a risk of Torsades de Pointes,or a history of long QT syndrome
- Medical history of difficulty swallowing, malabsorption or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the tested product
- Participation in an investigational drug or device trial within 4 weeks prior to the trial entry
- Known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
- Recent venous thrombosis (including deep vein thrombosis or pulmonary embolism within 1 year of study)
- History of upper gastrointestinal hemorrhage, peptic ulcer disease, or bleeding diathesis
- Subject is pregnant (positive serum beta human chorionic gonadotropin [β-HCG] test at screening) or is currently breast-feeding, their partner anticipates becoming pregnant/impregnating during the trial or within 6 months after receiving the last dose of trial treatment
- Concomitant disease or condition that could interfere with the conduct of the trial, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this trial
- Unwillingness or inability to comply with the trial protocol for any reason
- Legal incapacity or limited legal capacity
- Cardiac disease with New York Heart Association (NYHA) Class III or IV, including congestive heart failure, myocardial infarction within 6 months prior to the trial entry, unstable arrhythmia, or symptomatic peripheral arterial vascular
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: MAX-40279
MAX-40279 is provided as a capsule for oral use at 5mg, 25mg. In the dose-escalation phase, patients will be enrolled sequentially into the 5 dose levels of MAX-40279 designated in this study: 20, 40, 70, 100 and 120 mg/day (3-6 patients per cohort),bid.For each dose level, a single dose of MAX-40279 will be first administered orally followed by 1 day observation, then continuous treatment will start 4 weeks treatment (per cycle). After completion of the dose escalation, additional patients will be enrolled into dose expansion at the Maximum tolerated dose(MTD), up to 12 patients will be enrolled into expansion cohorts. |
MAX-40279, is a multi-targeted kinase inhibitor inhibitor mainly target FLT3 and FGFR. It has a molecular weight of 496.56 Daltons, which has a formula of C24H25FN6O3S. MAX-40279 is yellow powder. It is insoluble in water, methanol, ethanol, 0.1 mol/L hydrochloride solution or 0.1% saline; very slightly soluble in methylene dichloride and sparingly soluble in dimethylformamide. It is stable under strong acid, strong alkali, high temperatures and exposure to light. MAX-40279 for clinical use is presented as a sterile yellow powder packaged in capsules at 5 mg, or 25 mg doses.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events (AEs)
Time Frame: 8 weeks
|
Incidence of treatment-related AEs
|
8 weeks
|
Maximum tolerated dose (MTD)
Time Frame: 4 weeks
|
MTD will be defined as the maximum dose level at which no more than 1 of 3 participants experience a dose-limiting toxicity (DLT) within the first 4 weeks of multiple dosing.
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tmax
Time Frame: First single dose(pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 24h post-dose), Cycle 1 Day 1 (the second dose)(pre-dose),Cycle 1 Day 15(pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 24h post-dose), Cycle 1 Day 28(pre-dose), Cycle 2 Day 28(pre-dose).
|
Time to maximum plasma concentration
|
First single dose(pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 24h post-dose), Cycle 1 Day 1 (the second dose)(pre-dose),Cycle 1 Day 15(pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 24h post-dose), Cycle 1 Day 28(pre-dose), Cycle 2 Day 28(pre-dose).
|
Cmax
Time Frame: First single dose(pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 24h post-dose), Cycle 1 Day 1 (the second dose)(pre-dose),Cycle 1 Day 15(pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 24h post-dose), Cycle 1 Day 28(pre-dose), Cycle 2 Day 28(pre-dose).
|
Maximum plasma drug concentration
|
First single dose(pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 24h post-dose), Cycle 1 Day 1 (the second dose)(pre-dose),Cycle 1 Day 15(pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 24h post-dose), Cycle 1 Day 28(pre-dose), Cycle 2 Day 28(pre-dose).
|
AUC
Time Frame: First single dose(pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 24h post-dose), Cycle 1 Day 1 (the second dose)(pre-dose),Cycle 1 Day 15(pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 24h post-dose), Cycle 1 Day 28(pre-dose), Cycle 2 Day 28(pre-dose).
|
Area under the time-concentration curve
|
First single dose(pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 24h post-dose), Cycle 1 Day 1 (the second dose)(pre-dose),Cycle 1 Day 15(pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 24h post-dose), Cycle 1 Day 28(pre-dose), Cycle 2 Day 28(pre-dose).
|
t1/2
Time Frame: First single dose(pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 24h post-dose), Cycle 1 Day 1 (the second dose)(pre-dose),Cycle 1 Day 15(pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 24h post-dose), Cycle 1 Day 28(pre-dose), Cycle 2 Day 28(pre-dose).
|
Observed terminal half-life
|
First single dose(pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 24h post-dose), Cycle 1 Day 1 (the second dose)(pre-dose),Cycle 1 Day 15(pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 24h post-dose), Cycle 1 Day 28(pre-dose), Cycle 2 Day 28(pre-dose).
|
p-FLT3 Y591
Time Frame: First single dose(pre-dose), Cycle 1 Day 15(pre-dose), Cycle 1 Day 28(pre-dose), Cycle 2 Day 28(pre-dose).
|
To examine the phosphorylation (activation) of either wild-type or mutated Fms-like Tyrosine Kinase-3(FLT3)
|
First single dose(pre-dose), Cycle 1 Day 15(pre-dose), Cycle 1 Day 28(pre-dose), Cycle 2 Day 28(pre-dose).
|
FGFR aberration
Time Frame: First single dose(pre-dose), Cycle 1 Day 15(pre-dose), Cycle 1 Day 28(pre-dose), Cycle 2 Day 28(pre-dose).
|
To detect Fibroblast growth factor receptor(FGFR) mutation
|
First single dose(pre-dose), Cycle 1 Day 15(pre-dose), Cycle 1 Day 28(pre-dose), Cycle 2 Day 28(pre-dose).
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Maxinovel
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myelogenous Leukemia (AML)
-
Eisai Inc.TerminatedPediatric Acute Myelogenous Leukemia (AML)United States, Canada, Australia
-
Kyowa Hakko Kirin Pharma, Inc.TerminatedAcute Myelogenous Leukemia (AML)United States
-
AbbVieGenentech, Inc.CompletedAcute Myeloid Leukemia | AML | Acute Myelogenous Leukemia
-
Merck Sharp & Dohme LLCTerminatedAcute Myelogenous Leukemia (AML)
-
Beth Israel Deaconess Medical CenterDana-Farber Cancer Institute; National Institutes of Health (NIH); Medivation... and other collaboratorsActive, not recruitingAML | Acute Myelogenous LeukemiaUnited States
-
Abramson Cancer Center of the University of PennsylvaniaTerminatedAcute Myelogenous Leukemia (AML)United States
-
Maxinovel Pty., Ltd.Recruiting
-
AbbVieGenentech, Inc.CompletedAML | Acute Myelogenous LeukemiaUnited States, Australia, Germany, Italy
-
Emory UniversityTeva Pharmaceuticals USATerminated
-
Sidney Kimmel Cancer Center at Thomas Jefferson...University of PennsylvaniaCompleted
Clinical Trials on MAX-40279
-
Maxinovel Pty., Ltd.RecruitingGastric Cancer | Gastroesophageal Junction CancerChina
-
Maxinovel Pty., Ltd.Not yet recruitingMetastatic Colorectal CancerChina
-
Maxinovel Pty., Ltd.Recruiting
-
Maxinovel Pty., Ltd.Recruiting
-
Maxinovel Pty., Ltd.Recruiting
-
Maxinovel Pty., Ltd.Not yet recruitingAdvanced / Metastatic Solid Tumors
-
Maxinovel Pty., Ltd.RecruitingAcute Myeloid Leukemia | Leukemia | Myelodysplastic Syndrome | Relapsed/Refractory Acute Myeloid LeukemiaChina
-
Maxinovel Pty., Ltd.Recruiting
-
Maxinovel Pty., Ltd.Recruiting
-
Maxinovel Pty., Ltd.Not yet recruitingAlopecia Areata